Search - tctmd.com

Displaying 521 - 540 of 715

Sort: Relevancy | Date

News Daily News

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

July 10, 2012

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Daily News

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

July 03, 2012

News Daily News

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

June 26, 2012

News Industry News

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

June 26, 2012

News Daily News

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Jason Kahn

June 22, 2012

News Daily News

Signs Point to Relationship Between Clopidogrel Efficacy, Cigarette Smoking

Yael L. Maxwell

June 20, 2012

News Daily News

Platelet Function Recovery Longer After Stopping Prasugrel Than Clopidogrel

June 14, 2012

News Daily News

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Caitlin E. Cox

June 07, 2012

News Daily News

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Caitlin E. Cox

June 07, 2012

News Daily News

Rivaroxaban May be Cost-Effective for A-fib Patients

L.A. McKeown

June 06, 2012

News Daily News

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

June 05, 2012

News Daily News

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

June 05, 2012

News Daily News

Post-Conditioning Decreases Infarct Size, Edema after Reperfusion Therapy for STEMI

Leah Lawrence

June 05, 2012

News Daily News

PLATO Substudy: ACS Patients with Prior Stroke at No Disadvantage with Ticagrelor

Yael L. Maxwell

June 01, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

News Daily News

GIFT Published: Role of CYP2C19 in Clopidogrel Response Variability Confirmed

L.A. McKeown

May 23, 2012

News Industry News

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

May 23, 2012

News Conference News EuroPCR 2012

Statin Reloading Improves Clinical Outcomes in Stable PCI Patients

Jason Kahn

May 17, 2012

Advertisement

Ticagrelor Provides More Potent Platelet Inhibition Than Prasugrel

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

PLATO Subanalysis: Ticagrelor Cost-Effective in ACS Patients

Treatment With Brilinta (Ticagrelor) For 12 Months Is Cost-Effective Versus Generic Clopidogrel, Europe New Data Shows

RE-LY: Dabigatran Shortens Drug Interruption with No Increased Bleeding

Signs Point to Relationship Between Clopidogrel Efficacy, Cigarette Smoking

Platelet Function Recovery Longer After Stopping Prasugrel Than Clopidogrel

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Antithrombotic Choice During PCI Influences Outcomes in Poor Clopidogrel Responders

Rivaroxaban May be Cost-Effective for A-fib Patients

Un Meta Análisis Favorece el Abciximab Intracoronario frente al Abciximab Intravenoso en PCI Primarias

Meta-analysis Favors Intracoronary vs. Intravenous Abciximab in Primary PCI

Post-Conditioning Decreases Infarct Size, Edema after Reperfusion Therapy for STEMI

PLATO Substudy: ACS Patients with Prior Stroke at No Disadvantage with Ticagrelor

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

Watchman Works Just as Well Without Warfarin-Protected Transition

GIFT Published: Role of CYP2C19 in Clopidogrel Response Variability Confirmed

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Statin Reloading Improves Clinical Outcomes in Stable PCI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content